Meeting
2018 ASCO Annual Meeting
Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study).
Authors
Ignacio Romero
Instituto Valenciano de Oncología (IVO), Valencia, Spain
Ignacio Romero , M. Jesús Rubio , Manuel Medina , Raquel Serrano , Eva Mª Guerra , Alfonso Cortes Salgado , Belén Pérez , Lucas Minig , Antonio Casado , Pluvio Coronado , Juan Fernando Cueva , Ana Vilar , Aureli Torné , Jaume Ordi , Sara Cros , Gaspar Salinas , Maria Santacana , Juan Antonio Schoenenberger-Arnaiz , Antonio Llombart-Cussac , Andres Poveda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Other Gynecologic Cancer
Clinical Trial Registration Number
NCT02506816
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5598)
DOI
10.1200/JCO.2018.36.15_suppl.5598
Abstract #
5598
Poster Bd #
325
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.
First Author: Helen Mackay
Poster
2015 ASCO Annual Meeting
Multi-gene panel testing in an unselected endometrial cancer cohort.
First Author: Kari Lassen Ring
Poster
2023 ASCO Annual Meeting
A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer.
First Author: Bradley Corr
Poster
2023 ASCO Annual Meeting
A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.
First Author: Elias Chandran